

Ref: Syn/CS/SE/Reg 30/2025-26/Mar/07

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 & 3,  
Bommasandra Industrial Area, IV Phase,  
Jigani Link Road, Bengaluru 560 099,  
Karnataka, India  
T +91 80 6891 9191  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

March 27, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

**Sub: Intimation of Leadership Changes**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors, pursuant to the recommendation of the Nomination and Remuneration Committee (‘NRC’) approved/ took note of the following:

- i. Change of role of Ms. Kiran Mazumdar Shaw, from Non-Executive Chairperson to Executive Chairperson (a Key Managerial Personnel) of the Company, subject to the approval of the shareholders of the Company.
- ii. Resignation of Mr. Peter Bains from the position of Managing Director & Chief Executive Officer of the Company, effective from close of business hours on June 30, 2026.
- iii. Appointment of Mr. Siddharth Mittal as an Additional Director, designated as Managing Director & Chief Executive Officer (a Key Managerial Personnel) of the Company and a member of the Executive Committee, effective July 01, 2026, subject to the approval of the shareholders of the Company.

In accordance with SEBI letter dated June 14, 2018, read along with NSE Circular dated June 20, 2018, having ref no. as - NSE/CML/2018/24, we hereby confirm that Mr. Siddharth Mittal is not debarred from holding the office of director by virtue of any order of SEBI or any other authority.

The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations, SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed in **Annexure 1**.

The above information will also be made available on the website of the Company at [www.syngeneintl.com](http://www.syngeneintl.com).

Kindly take the above information on record.

Thanking You

Yours faithfully,

**For SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Chethan Yogesh  
**Company Secretary & Compliance Officer**  
Encl: a/a

**Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:**

**i. Ms. Kiran Mazumdar Shaw**

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, <del>re-appointment,</del> resignation, <del>removal,</del> death or otherwise)	Change of role of Ms. Kiran Mazumdar Shaw, from Non-Executive Chairperson to Executive Chairperson (a Key Managerial Personnel) of the Company.
2.	Date of appointment/ <del>re-appointment/cessation</del> (as applicable) & term of appointment/ <del>re-appointment;</del>	With effect from April 01, 2026, for a period of 5 years
3.	Brief profile	Brief profile attached as <b>Annexure 1A</b>
4.	Disclosure of relationships between directors (in case of appointment)	NIL

**ii. Mr. Peter Bains**

Sr. No.	Particulars	Details
1.	Reason for change (viz. <del>appointment,</del> <del>re-appointment,</del> resignation, <del>removal,</del> death or otherwise)	Resignation of Mr. Peter Bains from the position of Managing Director & Chief Executive Officer of the Company, effective from close of business hours on June 30, 2026.
2.	<del>Date of appointment/re-appointment/cessation</del> (as applicable) & term of <del>appointment/re-appointment;</del>	Effective from close of business hours on June 30, 2026
3.	Brief profile	NA
4.	Disclosure of relationships between directors (in case of appointment)	NA

### iii. Mr. Siddharth Mittal

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment of Mr. Siddharth Mittal as an Additional Director, designated as Managing Director & Chief Executive Officer (a Key Managerial Personnel) and a member of the Executive Committee with effect from July 01, 2026.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Appointment with effect from July 01, 2026, for a period of 5 years.
3.	Brief profile	Brief profile attached as <b>Annexure 1B</b>
4.	Disclosure of relationships between directors (in case of appointment)	NIL

**Annexure 1A**

### Brief Profile of Ms. Kiran Mazumdar Shaw

Kiran Mazumdar Shaw is the Executive Chairperson and founder of Biocon Group. She has over four decades of experience in biotechnology and has led the Company since its inception in 1978. Under her leadership, Biocon has evolved into a global biopharmaceutical enterprise focused on innovation and affordable healthcare. She has received several national and international honours, including the Padma Shri and Padma Bhushan.

Her leadership has brought significant global recognition to both Indian industry and her company.

Ms. Kiran Mazumdar Shaw continues to contribute actively through key roles across industry, academia, government, and professional bodies, further shaping the future of healthcare and innovation.

**Annexure 1B**

### Brief Profile of Mr. Siddharth Mittal:

Prior to this appointment, Mr. Siddharth Mittal served as Managing Director and CEO of Biocon Limited. He joined the Company in May 2013 and served as President & Chief Financial Officer until November 2019. He brings over two decades of experience in strategic finance, M&A, and general management. During his tenure, he contributed to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under Siddharth's leadership, Biocon moved decisively into complex peptides and GLP-1 therapies, stepping into one of the most strategically significant segments in modern pharma. He also led the Company's entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets.